Literature DB >> 7898219

Parvovirus B19 infection during pregnancy treated with high-dose intravenous gammaglobulin.

A Selbing, A Josefsson, L O Dahle, R Lindgren.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7898219     DOI: 10.1016/s0140-6736(95)90569-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  7 in total

Review 1.  Passive immunity in prevention and treatment of infectious diseases.

Authors:  M A Keller; E R Stiehm
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

Review 2.  Parvovirus B19 infection in human pregnancy.

Authors:  R F Lamont; J D Sobel; E Vaisbuch; J P Kusanovic; S Mazaki-Tovi; S K Kim; N Uldbjerg; R Romero
Journal:  BJOG       Date:  2010-10-13       Impact factor: 6.531

Review 3.  Current treatment options in (peri)myocarditis and inflammatory cardiomyopathy.

Authors:  B Maisch; S Pankuweit
Journal:  Herz       Date:  2012-09       Impact factor: 1.443

Review 4.  Standard and etiology-directed evidence-based therapies in myocarditis: state of the art and future perspectives.

Authors:  Bernhard Maisch; Sabine Pankuweit
Journal:  Heart Fail Rev       Date:  2013-11       Impact factor: 4.214

5.  Parvovirus B19 infection presenting with severe erythroid aplastic crisis during pregnancy in a woman with autoimmune hemolytic anemia and alpha-thalassemia trait: a case report.

Authors:  Chi-Ching Chen; Chin-Shan Chen; Wei-Yao Wang; Jui-Shan Ma; Hwei-Fan Shu; Frank S Fan
Journal:  J Med Case Rep       Date:  2015-03-12

Review 6.  Treatment options in myocarditis and inflammatory cardiomyopathy : Focus on i. v. immunoglobulins.

Authors:  B Maisch; P Alter
Journal:  Herz       Date:  2018-08       Impact factor: 1.443

Review 7.  A Toolbox of Potential Immune-Related Therapies for Inflammatory Cardiomyopathy.

Authors:  Ahmed Elsanhoury; Carsten Tschöpe; Sophie Van Linthout
Journal:  J Cardiovasc Transl Res       Date:  2020-05-21       Impact factor: 4.132

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.